Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study

Konstantinos Tryfonidis; S. Marreaud; H. Khaled; B. De Valk; J. Vermorken; M. Welnicka-jaskiewicz; K. Aalders; J. M. S. Bartlett; L. Biganzoli; J. Bogaerts; David Cameron

doi:10.1007/s10549-017-4203-y

Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study

Konstantinos Tryfonidis, S. Marreaud, H. Khaled, B. De Valk, J. Vermorken, M. Welnicka-jaskiewicz, K. Aalders, J. M. S. Bartlett, L. Biganzoli, J. Bogaerts, David Cameron

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Breast cancer research and treatment
DOIs	https://doi.org/10.1007/s10549-017-4203-y
Publication status	Published - 21 Mar 2017

Access to Document

10.1007/s10549-017-4203-y

10995 ORIGINAL ARTICLE MANUSCRIPT
This is the authors final peer-reviewed manuscript as accepted for publication.
Accepted author manuscript, 862 KB

http://link.springer.com/10.1007/s10549-017-4203-y

Cite this

Tryfonidis, K., Marreaud, S., Khaled, H., De Valk, B., Vermorken, J., Welnicka-jaskiewicz, M., Aalders, K., Bartlett, J. M. S., Biganzoli, L., Bogaerts, J., & Cameron, D. (2017). Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study. Breast cancer research and treatment. https://doi.org/10.1007/s10549-017-4203-y

Tryfonidis, Konstantinos ; Marreaud, S. ; Khaled, H. et al. / Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study. In: Breast cancer research and treatment. 2017.

@article{1efd3d8a02394565914a9a9ad1fdbb6e,

title = "Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study",

author = "Konstantinos Tryfonidis and S. Marreaud and H. Khaled and {De Valk}, B. and J. Vermorken and M. Welnicka-jaskiewicz and K. Aalders and Bartlett, {J. M. S.} and L. Biganzoli and J. Bogaerts and David Cameron",

year = "2017",

month = mar,

day = "21",

doi = "10.1007/s10549-017-4203-y",

language = "English",

journal = "Breast cancer research and treatment",

issn = "0167-6806",

publisher = "Springer",

}

Tryfonidis, K, Marreaud, S, Khaled, H, De Valk, B, Vermorken, J, Welnicka-jaskiewicz, M, Aalders, K, Bartlett, JMS, Biganzoli, L, Bogaerts, J & Cameron, D 2017, 'Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study', Breast cancer research and treatment. https://doi.org/10.1007/s10549-017-4203-y

Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study. / Tryfonidis, Konstantinos; Marreaud, S.; Khaled, H. et al.
In: Breast cancer research and treatment, 21.03.2017.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study

AU - Tryfonidis, Konstantinos

AU - Marreaud, S.

AU - Khaled, H.

AU - De Valk, B.

AU - Vermorken, J.

AU - Welnicka-jaskiewicz, M.

AU - Aalders, K.

AU - Bartlett, J. M. S.

AU - Biganzoli, L.

AU - Bogaerts, J.

AU - Cameron, David

PY - 2017/3/21

Y1 - 2017/3/21

U2 - 10.1007/s10549-017-4203-y

DO - 10.1007/s10549-017-4203-y

M3 - Article

SN - 0167-6806

JO - Breast cancer research and treatment

JF - Breast cancer research and treatment

ER -

Tryfonidis K, Marreaud S, Khaled H, De Valk B, Vermorken J, Welnicka-jaskiewicz M et al. Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study. Breast cancer research and treatment. 2017 Mar 21. doi: 10.1007/s10549-017-4203-y